Raymond James Downgrades ChemoCentryx (CCXI) to Outperform

Go back to Raymond James Downgrades ChemoCentryx (CCXI) to Outperform

ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms

May 7, 2021 9:36 AM EDT

Shares of ChemoCentryx (NASDAQ: CCXI) crashed 55% in pre-open Friday after the Food and Drug Administration (FDA) raised concerns over the approval application of the product avacopan.

We are grateful to the Committee for their careful deliberations and look forward to working with the FDA as its review of our application continues, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. Discussion from patients and clinicians during the public forum portion of the meeting underscored the need for new treatment options.

The FDA is primarily concerned that the therapy could not... More

ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom

May 7, 2021 7:15 AM EDT

ChemoCentryx (NASDAQ: CCXI) sinks 45% as trading resumes following mixed FDA AdCom.

... More

SVB Leerink Downgrades ChemoCentryx (CCXI) to Market Perform

May 7, 2021 7:01 AM EDT

SVB Leerink analyst Joseph Schwartz downgraded ChemoCentryx (NASDAQ: CCXI) from Outperform to Market Perform with a price target of $17.00.


For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.


Shares of ChemoCentryx closed at $27.49 yesterday.

... More

ChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan

May 7, 2021 6:48 AM EDT

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA:

The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with... More

UPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold

May 7, 2021 4:01 AM EDT

(Updated - May 7, 2021 5:14 AM EDT)

Stifel analyst Dae Gon Ha downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Hold with a price target of $26.00 (from $93.00).

THe analyst comments "We are downgrading CCXI to Hold (from Buy) with a reduced TP $26 (from $93 previously) following a... More

UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight

May 7, 2021 4:01 AM EDT

(Updated - May 7, 2021 5:12 AM EDT)

JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Neutral to Underweight with a price target of $17.00 (from $57.00).

The analyst comments "We hold an Underweight rating on CCXI shares. ChemoCentryx is a biotechnology company with a focus on developing oral drugs that target the chemokine system, which is... More

Piper Sandler Downgrades ChemoCentryx (CCXI) to Neutral

May 6, 2021 7:04 PM EDT

Piper Sandler analyst Edward Tenthoff downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $25.00.


For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.


Shares of ChemoCentryx closed at $27.49 yesterday.

... More